For years, peanut allergy treatments have dominated the headlines, leaving families with other food allergies wondering when their turn would come. A new study published in the February 2026 supplement of the Journal of Allergy and Clinical Immunology, titled “Sustained Unresponsiveness Profiles Following Non-Peanut Food OIT,” shifts the focus. The research examines how children can achieve sustained unresponsiveness (SU) to seeds, tree nuts, dairy, and other non-peanut allergens.
The research team set out to address a clear gap in medical knowledge. Although peanut oral immunotherapy (OIT) has been extensively studied, long-term data on other foods remain limited. As the authors explain, “We sought to evaluate OIT-induced SU across a broader spectrum of foods,” thereby expanding the conversation beyond peanut allergy alone.
To do so, investigators conducted a retrospective review of 106 pediatric patients at a single food allergy center. The children, with a median age of 3 years, underwent 117 sustained unresponsiveness oral food challenges (SU OFCs). The study included sesame (45 cases), cashew (29), and walnut (19), along with milk, egg, wheat, and smaller numbers of other seeds and tree nuts.
The results showed significant declines in skin prick test (SPT) wheal size from the start of OIT to the time of sustained unresponsiveness testing for nearly all foods studied, except wheat. Cashew and sesame showed particularly notable reductions in sensitivity.
Achieving sustained protection required a prolonged maintenance phase, during which children continued daily dosing with the allergen. The median maintenance duration before SU testing was approximately 21.4 months for milk, 21.3 months for egg, and 20.5 months for tree nuts (with seeds averaging slightly less). These findings reinforce that OIT is a long-term commitment rather than a short-term intervention.
Among patients who underwent the sustained unresponsiveness oral food challenge, the pass rate was 100% across all foods studied. This indicates a high success rate among those who reached the SU testing phase, though the abstract does not report discontinuation rates before that point.
In their conclusion, the authors describe OIT’s success across multiple allergens as “remarkably robust.” By documenting sustained unresponsiveness beyond peanut, this study helps fill important knowledge gaps regarding long-term outcomes for children with allergies to milk, egg, seeds, and tree nuts.
What This Means for Families
For families managing non-peanut food allergies, this study offers encouraging news: oral immunotherapy may provide a path to sustained protection against a broader range of allergens than previously documented. Importantly, “sustained unresponsiveness” means that some children may be able to stop daily dosing for a period of time and still pass a supervised food challenge.
That said, OIT remains a medical treatment that requires careful supervision by an experienced allergist, consistent daily dosing, and a long-term commitment. The process can take nearly two years or longer before testing for sustained unresponsiveness.
Parents considering OIT should discuss with their child’s allergist:
- Whether their child is a good candidate
- The expected timeline and maintenance requirements
- The risks of reactions during treatment
- How success is defined in their specific program
While OIT is not a cure, studies like this suggest that durable tolerance may be achievable for more foods than just peanut — offering hope and expanded options to families navigating complex food allergies.
